Creatinine-Cystatin C Discrepancy and Renal Transporter Polymorphisms in Japanese Patients with Breast Cancer Receiving Abemaciclib. (PubMed, Clin Pharmacol Ther) - Sep 24, 2026 - "The pre-treatment serum creatinine/cystatin C ratio predicted the on-treatment discrepancy, and SLC47A1 rs2289669 GG was associated with a greater rise, consistent with a MATE1-mediated mechanism. Because a fixed cross-sectional threshold does not separate treatment-associated discrepancy from pre-existing discrepancy, a pre-treatment cystatin C measurement is needed to interpret serum creatinine elevation during abemaciclib therapy."
Journal • Breast Cancer • Oncology • Solid Tumor • CST3 • SLC22A2
|
|
Hiroaki Watanabe; Keita Hirai; Ken-Ichi Ito; Mayu Ono; Takaaki Oba; Takafumi Naito
|